240 related articles for article (PubMed ID: 21048153)
1. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia.
Shanafelt TD; Drake MT; Maurer MJ; Allmer C; Rabe KG; Slager SL; Weiner GJ; Call TG; Link BK; Zent CS; Kay NE; Hanson CA; Witzig TE; Cerhan JR
Blood; 2011 Feb; 117(5):1492-8. PubMed ID: 21048153
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma.
Drake MT; Maurer MJ; Link BK; Habermann TM; Ansell SM; Micallef IN; Kelly JL; Macon WR; Nowakowski GS; Inwards DJ; Johnston PB; Singh RJ; Allmer C; Slager SL; Weiner GJ; Witzig TE; Cerhan JR
J Clin Oncol; 2010 Sep; 28(27):4191-8. PubMed ID: 20713849
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL).
Molica S; Digiesi G; Antenucci A; Levato L; Mirabelli R; Molica M; Gentile M; Giannarelli D; Sperduti I; Morabito F; Conti L
Leuk Res; 2012 Apr; 36(4):443-7. PubMed ID: 22047708
[TBL] [Abstract][Full Text] [Related]
4. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.
Shanafelt TD; Geyer SM; Bone ND; Tschumper RC; Witzig TE; Nowakowski GS; Zent CS; Call TG; Laplant B; Dewald GW; Jelinek DF; Kay NE
Br J Haematol; 2008 Mar; 140(5):537-46. PubMed ID: 18275431
[TBL] [Abstract][Full Text] [Related]
5. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia.
Gattei V; Bulian P; Del Principe MI; Zucchetto A; Maurillo L; Buccisano F; Bomben R; Dal-Bo M; Luciano F; Rossi FM; Degan M; Amadori S; Del Poeta G
Blood; 2008 Jan; 111(2):865-73. PubMed ID: 17959854
[TBL] [Abstract][Full Text] [Related]
6. Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients.
Meuleman N; Stamatopoulos B; Dejeneffe M; El Housni H; Lagneaux L; Bron D
Leukemia; 2008 Oct; 22(10):1882-90. PubMed ID: 18633433
[TBL] [Abstract][Full Text] [Related]
7. CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Gooden CE; Jones P; Bates R; Shallenberger WM; Surti U; Swerdlow SH; Roth CG
Cytometry B Clin Cytom; 2018 Jan; 94(1):129-135. PubMed ID: 27221715
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.
Weinberg JB; Volkheimer AD; Chen Y; Beasley BE; Jiang N; Lanasa MC; Friedman D; Vaccaro G; Rehder CW; Decastro CM; Rizzieri DA; Diehl LF; Gockerman JP; Moore JO; Goodman BK; Levesque MC
Am J Hematol; 2007 Dec; 82(12):1063-70. PubMed ID: 17654680
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of serum immunoglobulin paraprotein in patients with chronic lymphocytic leukemia.
Xu W; Wang YH; Fan L; Fang C; Zhu DX; Wang DM; Qiao C; Wu YJ; Li JY
Leuk Res; 2011 Aug; 35(8):1060-5. PubMed ID: 21208658
[TBL] [Abstract][Full Text] [Related]
10. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.
Bulian P; Shanafelt TD; Fegan C; Zucchetto A; Cro L; Nückel H; Baldini L; Kurtova AV; Ferrajoli A; Burger JA; Gaidano G; Del Poeta G; Pepper C; Rossi D; Gattei V
J Clin Oncol; 2014 Mar; 32(9):897-904. PubMed ID: 24516016
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of serum 25-hydroxivitamin D [25(OH)D] concentrations in patients with lymphoid malignancies.
Aref S; Ibrahim L; Azmy E
Hematology; 2013 Jan; 18(1):20-5. PubMed ID: 22980447
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia.
Molica S; Vitelli G; Cutrona G; Todoerti K; Mirabelli R; Digiesi G; Giannarelli D; Sperduti I; Molica M; Gentile M; Morabito F; Neri A; Ferrarini M
Int J Hematol; 2008 Nov; 88(4):374-380. PubMed ID: 18818986
[TBL] [Abstract][Full Text] [Related]
13. CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia.
Buhl AM; Jurlander J; Geisler CH; Pedersen LB; Andersen MK; Josefsson P; Petersen JH; Leffers H
Eur J Haematol; 2006 Jun; 76(6):455-64. PubMed ID: 16529606
[TBL] [Abstract][Full Text] [Related]
14. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.
Rassenti LZ; Jain S; Keating MJ; Wierda WG; Grever MR; Byrd JC; Kay NE; Brown JR; Gribben JG; Neuberg DS; He F; Greaves AW; Rai KR; Kipps TJ
Blood; 2008 Sep; 112(5):1923-30. PubMed ID: 18577710
[TBL] [Abstract][Full Text] [Related]
15. Most morphologic features in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) do not reliably predict underlying FISH genetics or immunoglobulin heavy chain variable region somatic mutational status.
Garcia CF; Hunt KE; Kang H; Babb A; Gale JM; Vasef MA; Reichard KK
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):119-27. PubMed ID: 19826250
[TBL] [Abstract][Full Text] [Related]
16. Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study.
Gentile M; Cutrona G; Fabris S; Pesce EA; Baldini L; Di Raimondo F; Musolino C; Di Tonno P; Di Renzo N; Molica S; Brugiatelli M; Ilariucci F; Zupo S; Matis S; Maura F; Vigna E; Angrilli F; Recchia AG; Quarta G; Iannitto E; Fragasso A; Musto P; Spriano M; Vincelli I; Vallisa D; Cortelezzi A; Mauro FR; Foà R; Federico M; Neri A; Ferrarini M; Morabito F
Am J Hematol; 2013 Jul; 88(7):539-44. PubMed ID: 23553682
[TBL] [Abstract][Full Text] [Related]
17. FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.
Li FJ; Ding S; Pan J; Shakhmatov MA; Kashentseva E; Wu J; Li Y; Soong SJ; Chiorazzi N; Davis RS
Blood; 2008 Jul; 112(1):179-87. PubMed ID: 18314442
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.
Lucas DM; Ruppert AS; Lozanski G; Dewald GW; Lozanski A; Claus R; Plass C; Flinn IW; Neuberg DS; Paietta EM; Bennett JM; Jelinek DF; Gribben JG; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS; Byrd JC; Grever MR
Leuk Lymphoma; 2015; 56(11):3031-7. PubMed ID: 25721902
[TBL] [Abstract][Full Text] [Related]
19. Quantification of ZAP-70 expression in chronic lymphocytic leukemia: T/B-cell ratio of mean fluorescence intensity provides stronger prognostic value than percentage of positive cells.
Smolej L; Vroblova V; Motyckova M; Jankovicova K; Schmitzova D; Krejsek J; Maly J
Neoplasma; 2011; 58(2):140-5. PubMed ID: 21275464
[TBL] [Abstract][Full Text] [Related]
20. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.
Claus R; Lucas DM; Ruppert AS; Williams KE; Weng D; Patterson K; Zucknick M; Oakes CC; Rassenti LZ; Greaves AW; Geyer S; Wierda WG; Brown JR; Gribben JG; Barrientos JC; Rai KR; Kay NE; Kipps TJ; Shields P; Zhao W; Grever MR; Plass C; Byrd JC
Blood; 2014 Jul; 124(1):42-8. PubMed ID: 24868078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
